Payment overview · 2025
General Payments
$673.76
38 reported records · 21 companies
Healthcare provider profile · identity verified
Ish Rawal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CANTON, OH · NPI 1467679589
Verified facts
What the public records show
CMS Open Payments records show Ish Rawal, MD received $673.76 in general payments during 2025 across 38 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $137.16 | 20.4% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.36 | 14.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.01 | 7.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.20 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.87 | 5.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.20 | 4.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.68 | 4.5% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.75 | 4.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.04 | 3.3% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $20.81 | 3.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.07 | 3.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.96 | 3.0% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $19.33 | 2.9% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $17.06 | 2.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.46 | 2.4% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.25 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.02 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.64 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.55 | 2.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.33 | 2.1% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $14.01 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $673.76 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $137.16 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.01 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.20 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.87 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $38.50 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.72 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.20 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $26.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| REJOYN Normalized: rejoyn |
Device | Otsuka Pharmaceutical Development & Commercialization, Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 140 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
140 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
140 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 428 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 315 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 214 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 212 | 44 |
| Lisinopril | Lisinopril | 197 | 55 |
| Gabapentin | Gabapentin | 193 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 190 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 34 |
| Potassium Chloride | Potassium Chloride | 173 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 44 |
| Sertraline Hcl | Sertraline Hcl | 162 | 42 |
| Furosemide | Furosemide | 150 | 49 |
| Metformin Hcl | Metformin Hcl | 150 | 37 |
| Buspirone Hcl | Buspirone Hcl | 146 | 22 |
| Eliquis | Apixaban | 140 | 39 |
| Omeprazole | Omeprazole | 134 | 39 |
| Trazodone Hcl | Trazodone Hcl | 134 | 30 |
| Mirtazapine | Mirtazapine | 132 | 20 |
| Donepezil Hcl | Donepezil Hcl | 130 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 27 |
| Losartan Potassium | Losartan Potassium | 105 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 16 |
| Allopurinol | Allopurinol | 93 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 15 |
| Carvedilol | Carvedilol | 86 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 83 | suppressed |
| Lorazepam | Lorazepam | 83 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 23 |
| Simvastatin | Simvastatin | 80 | 18 |
| Famotidine | Famotidine | 73 | 20 |
| Finasteride | Finasteride | 67 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 16 |
| Baclofen | Baclofen | 64 | 13 |
| Prednisone | Prednisone | 59 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 11 |
| Memantine Hcl | Memantine Hcl | 56 | 12 |
| Olanzapine | Olanzapine | 56 | suppressed |
| Levetiracetam | Levetiracetam | 55 | 17 |
| Alendronate Sodium | Alendronate Sodium | 54 | suppressed |
| Alprazolam | Alprazolam | 54 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 13 |
| Jardiance | Empagliflozin | 53 | 17 |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Atenolol | Atenolol | 49 | suppressed |
| Ezetimibe | Ezetimibe | 48 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 11 |
| Glimepiride | Glimepiride | 47 | 14 |
| Amantadine | Amantadine Hcl | 46 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Cephalexin | Cephalexin | 44 | 29 |
| Montelukast Sodium | Montelukast Sodium | 44 | 17 |
| Morphine Sulfate | Morphine Sulfate | 44 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | 12 |
| Topiramate | Topiramate | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 13 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 18 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 23 |
| Invega Sustenna | Paliperidone Palmitate | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | 11 |
| Meloxicam | Meloxicam | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 11 |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | 12 |
| Amoxicillin | Amoxicillin | 16 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Ozempic | Semaglutide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $673.76 · 38 records | Teva Pharmaceuticals USA, Inc. | ALVESCO, AUSTEDO XR, BEXSERO, CAPVAXIVE, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, Dyanavel XR, ELIQUIS, FARXIGA, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, Kerendia, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, QULIPTA, Qelbree, REJOYN, REXULTI, UBRELVY, VRAYLAR, Wegovy, Xhance, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error